Crescent Biopharma, Inc. (CBIO) Research

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Market snapshot

Symbol
CBIO
Price
$17.69
Day change
-2.86%
Market cap
$487.7M
P/E ratio
-3.32x
52-week range
8.72-27.41
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$33.00

Peer companies

  • Armata Pharmaceuticals, Inc. (ARMP)
  • C4 Therapeutics, Inc. (CCCC)
  • Compugen Ltd. (CGEN)
  • Vyome Holdings, Inc. (HIND)
  • Heron Therapeutics, Inc. (HRTX)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Innate Pharma S.A. (IPHA)
  • OmniAb, Inc. (OABI)

Recent insider activity

  • Violin Jonathan — A-Award (11050 shares) on 2026-06-02
  • Lubner David Charles — A-Award (11050 shares) on 2026-06-02
  • Balcom Alexandra — A-Award (11050 shares) on 2026-06-02
  • Moran Susan — A-Award (11050 shares) on 2026-06-02
  • Fairmount Funds Management LLC — A-Award (11050 shares) on 2026-06-02

Open Crescent Biopharma, Inc. (CBIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.